E-ISSN 2146-9369 | ISSN 2146-3158
 
2024, Vol: 14, Issue: 2
14 / 2Current Issue ArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles

Research Article


Pre-treatment HIV-1 drug resistance in Cuban patients with late presentation to health care: 2009-2020.

Liuber Y Machado, Héctor M Díaz, Liodelvio Martínez, Madeline Blanco, Marta Dubed, Neisy Valdés, Karen Valdés, Laura S López, Enrique Noa, María T Pérez, Otto Cruz, Mireida Rodríguez.


Abstract
Background:
The presence of antiretroviral-resistant HIV-1 genetic variants in patients with late presentation to health care may impact the success of antiretroviral therapy, costs of care, and potential HIV transmission.
Aim:
To determine the prevalence of pre-treatment HIV-1 drug resistance to antiretrovirals (PDR) in Cuban patients classified as late presenters (LP).
Methods:
A retrospective cross-sectional study was carried out on 255 HIV-positive Cubans classified as LP (CD4+ T cell count ≤350 cells/mm3) and included in PDR surveillance studies in Cuba during the period 2009-2020. The viral subtype and the genotypic profile of antiretroviral resistance were analyzed. Some clinical and epidemiological variables were evaluated.
Results:
83.2% of the patients were male and 65.9% were men who had sex with other men (MSM). The average age was 31 years. 40% of the individuals studied had advanced disease (CD4+ T cell count ≤200 cells/mm3). The predominant genetic variants were subtype B (29.4%); CRF20, 23, 24_BG (24.3%) and CRF19_cpx (22.4%). The prevalence of PDR was 21.2% (95%, CI 16.3-26.7). The prevalence was 8.2% (95%, CI 5.3-11.9) for any Nucleoside Reverse Transcriptase Inhibitor (NRTI), 15.1 % (95%, CI 11.2-19.7) for any Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), 2.1 % (95%, CI 0.75-4.41) for any Protease Inhibitor (PI). 9.25% of the LPs with PDR died a year after diagnosis of the HIV infection. The most frequent mutations were K103N (6.7%), G190A (4.7%) and M184V (4.3%). The treatment will not be effective in 17.3 % of patients who start therapy with the NRTI+NNRTI combinations.
Conclusion:
The high PDR values in LPs show the need to enhance genotypic studies of HIV resistance in this population at the time of diagnosis of the infection, since the success of first-line antiretroviral therapy may be compromised and influence compliance with the global goals set forth by UNAIDS for the year 2030.

Key words: Cuba, Late presenters, Resistance, Antiretroviral therapy, HIV


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Liuber Y Machado
Articles by Héctor M Díaz
Articles by Liodelvio Martínez
Articles by Madeline Blanco
Articles by Marta Dubed
Articles by Neisy Valdés
Articles by Karen Valdés
Articles by Laura S López
Articles by Enrique Noa
Articles by María T Pérez
Articles by Otto Cruz
Articles by Mireida Rodríguez
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

LYM, Díaz HM, LM, Blanco M, Dubed M, Valdés N, Valdés K, López LS, Noa E, Pérez MT, Cruz O, Rodríguez M. Pre-treatment HIV-1 drug resistance in Cuban patients with late presentation to health care: 2009-2020.. J Microbiol Infect Dis. 2024; 14(2): 60-66. doi:10.5455/JMID.2024.v14.i2.4

Web Style

LYM, Díaz HM, LM, Blanco M, Dubed M, Valdés N, Valdés K, López LS, Noa E, Pérez MT, Cruz O, Rodríguez M. Pre-treatment HIV-1 drug resistance in Cuban patients with late presentation to health care: 2009-2020.. https://www.jmidonline.org/?mno=194137 [Access: July 06, 2024]. doi:10.5455/JMID.2024.v14.i2.4

AMA (American Medical Association) Style

LYM, Díaz HM, LM, Blanco M, Dubed M, Valdés N, Valdés K, López LS, Noa E, Pérez MT, Cruz O, Rodríguez M. Pre-treatment HIV-1 drug resistance in Cuban patients with late presentation to health care: 2009-2020.. J Microbiol Infect Dis. 2024; 14(2): 60-66. doi:10.5455/JMID.2024.v14.i2.4


Vancouver/ICMJE Style

LYM, Díaz HM, LM, Blanco M, Dubed M, Valdés N, Valdés K, López LS, Noa E, Pérez MT, Cruz O, Rodríguez M. Pre-treatment HIV-1 drug resistance in Cuban patients with late presentation to health care: 2009-2020.. J Microbiol Infect Dis. (2024), [cited July 06, 2024]; 14(2): 60-66. doi:10.5455/JMID.2024.v14.i2.4


Harvard Style

, L. Y. M., Díaz, . H. M., , . L. M., Blanco, . M., Dubed, . M., Valdés, . N., Valdés, . K., López, . L. S., Noa, . E., Pérez, . M. T., Cruz, . O. & Rodríguez, . M. (2024) Pre-treatment HIV-1 drug resistance in Cuban patients with late presentation to health care: 2009-2020.. J Microbiol Infect Dis, 14 (2), 60-66. doi:10.5455/JMID.2024.v14.i2.4


Turabian Style

, Liuber Y Machado, Héctor M Díaz, Liodelvio Martínez, Madeline Blanco, Marta Dubed, Neisy Valdés, Karen Valdés, Laura S López, Enrique Noa, María T Pérez, Otto Cruz, and Mireida Rodríguez. 2024. Pre-treatment HIV-1 drug resistance in Cuban patients with late presentation to health care: 2009-2020.. Journal of Microbiology and Infectious Diseases, 14 (2), 60-66. doi:10.5455/JMID.2024.v14.i2.4


Chicago Style

, Liuber Y Machado, Héctor M Díaz, Liodelvio Martínez, Madeline Blanco, Marta Dubed, Neisy Valdés, Karen Valdés, Laura S López, Enrique Noa, María T Pérez, Otto Cruz, and Mireida Rodríguez. "Pre-treatment HIV-1 drug resistance in Cuban patients with late presentation to health care: 2009-2020.." Journal of Microbiology and Infectious Diseases 14 (2024), 60-66. doi:10.5455/JMID.2024.v14.i2.4


MLA (The Modern Language Association) Style

, Liuber Y Machado, Héctor M Díaz, Liodelvio Martínez, Madeline Blanco, Marta Dubed, Neisy Valdés, Karen Valdés, Laura S López, Enrique Noa, María T Pérez, Otto Cruz, and Mireida Rodríguez. "Pre-treatment HIV-1 drug resistance in Cuban patients with late presentation to health care: 2009-2020.." Journal of Microbiology and Infectious Diseases 14.2 (2024), 60-66. Print. doi:10.5455/JMID.2024.v14.i2.4


APA (American Psychological Association) Style

, L. Y. M., Díaz, . H. M., , . L. M., Blanco, . M., Dubed, . M., Valdés, . N., Valdés, . K., López, . L. S., Noa, . E., Pérez, . M. T., Cruz, . O. & Rodríguez, . M. (2024) Pre-treatment HIV-1 drug resistance in Cuban patients with late presentation to health care: 2009-2020.. Journal of Microbiology and Infectious Diseases, 14 (2), 60-66. doi:10.5455/JMID.2024.v14.i2.4


Author LoginReviewer LoginAbout PublisherOpen Access PolicyEditorial PoliciesPeer Review PolicyPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About Journal of Microbiology and Infectious Diseases

Journal of Microbiology and Infectious Diseases (JMID) is an international "peer review" journal in microbiology, infectious diseases, virology, ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information

All correspondence should be addressed to:

Prof. Ibrahim Eldaghayes

Editor-in-Chief

Journal of Microbiology and Infectious Diseases

Department of Microbiology and Parasitology 

Faculty of Veterinary Medicine

University of Tripoli

P.O. Box 13662, Tripoli, Libya